HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway

Files in This Item:
22160_1_merged_1473263873_HUSCAP.pdf3.63 MBPDFView/Open
SupplementaryFigure1.jpgSupplementary Figure 1557.36 kBJPEGView/Open
SupplementaryFigure2.jpgSupplementary Figure 21.52 MBJPEGView/Open
SupplementaryFigure3.jpgSupplementary Figure 31.13 MBJPEGView/Open
SupplementaryFigure4.jpgSupplementary Figure 41.46 MBJPEGView/Open
SupplementaryFigure5.jpgSupplementary Figure 51.97 MBJPEGView/Open
SupplementaryFigure6.jpgSupplementary Figure 62.74 MBJPEGView/Open
SupplementaryFigure7.jpgSupplementary Figure 7911.79 kBJPEGView/Open
SupplementaryFigure8.jpgSupplementary Figure 81.29 MBJPEGView/Open
SupplementaryFigure9.jpgSupplementary Figure 9728.07 kBJPEGView/Open
SupplementaryTable1.jpgSupplementary Table 1317.27 kBJPEGView/Open
Please use this identifier to cite or link to this item:

Title: Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b+Ly6G+ intratumor myeloid cells through the TICAM-1 signaling pathway
Other Titles: CD11b+Ly6G+ cells induced by dsRNA
Authors: Shime, Hiroaki Browse this author →KAKEN DB
Matsumoto, Misako Browse this author →KAKEN DB
Seya, Tsukasa Browse this author →KAKEN DB
Keywords: Toll-like receptor
tumor-associated myeloid cells
type-I IFNs
Issue Date: Mar-2017
Publisher: Nature Publishing Group
Journal Title: Cell Death and Differentiation
Volume: 24
Issue: 3
Start Page: 385
End Page: 396
Publisher DOI: 10.1038/cdd.2016.131
Abstract: PolyI:C, a synthetic double-stranded RNA analog, acts as an immune-enhancing adjuvant that regresses tumors via cytotoxic T lymphocyte (CTL)-dependent and CTL-independent fashions, the latter of which remains largely unknown. Tumors contain CD11b+Ly6G+ cells, granulocytic myeloid-derived suppressor cells (G-MDSCs), or tumor-associated neutrophils (TANs), which play a critical role in tumor progression and development. Here, we demonstrate that CD11b+Ly6G+ cells respond to polyI:C and exhibit tumoricidal activity in an EL4 tumor implant model. PolyI:C-induced inhibition of tumor growth was attributed to caspase-8/3 cascade activation in tumor cells, which occurred independently of CD8α+/CD103+ dendritic cells (DCs) and CTLs. CD11b+Ly6G+ cells acted as anti-tumor effectors because depletion of CD11b+Ly6G+ cells totally abrogated tumor regression and caspase activation after polyI:C treatment. CD11b+Ly6G+ cells that had been activated with polyI:C showed cytotoxicity and inhibition of tumor growth through the production of reactive oxygen species (ROS)/reactive nitrogen species (RNS). These responses were abolished in either toll/interleukin-1 receptor domain-containing adaptor molecule-1 (TICAM-1)-/- or interferon (IFN)-αβ receptor 1 (IFNAR1)-/- mice. Thus, our results suggest that polyI:C targets myeloid cells in tumors, where CD11b+Ly6G+ cells exhibit anti-tumor activity through TLR3/TICAM-1 and IFNAR pathways, independent of those in CD8α+/CD103+ DCs that prime CTLs.
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 瀬谷 司

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University